Document is current
Any future updates will be listed below
-
Authors
Gao, Yudong
Shonai, Daichi
Trn, Matthew
Zhao, Jieqing
Soderblom, Erik J.
Garcia-Moreno, S. Alexandra
Gersbach, Charles A. https://orcid.org/0000-0003-1478-4013
Wetsel, William C. https://orcid.org/0000-0002-3592-7397
Dawson, Geraldine https://orcid.org/0000-0003-1410-2764
Velmeshev, Dmitry
Jiang, Yong-hui https://orcid.org/0000-0001-6188-8806
Sloofman, Laura G. https://orcid.org/0000-0001-7628-4378
Buxbaum, Joseph D. https://orcid.org/0000-0001-8898-8313
Soderling, Scott H. https://orcid.org/0000-0001-7808-197X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH111684)
- License Information
-
More Information
Article History
Received: 20 February 2024
Accepted: 23 July 2024
First Online: 9 August 2024
Competing interests
: S.H.S. and Y.G. have a patent application related to the HiUGE technology (16/968,904). The intellectual property was licensed to CasTag Biosciences. S.H.S. is a founder of CasTag Biosciences; Duke University as an institution holds equity in CasTag Biosciences. C.A.G. is an inventor on patents and patent applications related to CRISPR-based gene activation, is a co-founder of Tune Therapeutics, Locus Biosciences, and Element Genomics, and is an advisor to Sarepta Therapeutics. G.D. Dr. Dawson is on the Scientific Advisory Boards of Akili Interactive, Inc, and Tris Pharma, is a consultant to Apple, Gerson Lehrman Group, and Guidepoint Global, Inc. G.D. has developed autism-related technology, data, and/or products that have been licensed to Apple, Inc. and Cryocell, Inc. and Dawson and Duke University have benefited financially. J.D.B. is a consultant for Bridgebio. W.C.W. is a consultant for Onsero Therapeutics. The remaining authors declare no competing interests.
